Arcutis Biotherapeutics Inc (Arcutis) is a biopharmaceutical company. It is in developing small molecules for the treatment of immune-mediated dermatological diseases and conditions. Its pipeline products include a topical roflumilast cream, ARQ-252, a small molecule inhibitor of Janus kinase type 1 (JAK1) to treat rheumatoid arthritis, psoriasis, Crohn’s disease and atopic dermatitis and ARQ-255 for inflammation in alopecia areata. Arcutis other pipeline includes ARQ 252 for the treatment of chronic hand eczema.The company also investigating novel dermatology treatments in inflammation and immunology diseases. Arcutis is headquartered in Westlake Village, California, the US.
Headquarters
United States of America
Address
3027 Townsgate Road, Suite 300, Westlake Village, California, 91361
Website
arcutis.com
Telephone
1 805 4185006
No of Employees
296
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ARQT (NASD)
Revenue (2022)
$59.6M
1517.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
15.8%
(2022 vs 2021)
Market Cap*
$1.2B
Net Profit Margin (2022)
XYZ
94.8%
(2022 vs 2021)
* As of and is in US$
Arcutis Biotherapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Topical Roflumilast Cream - Palaque Psoaris and Atopic Dermatitis |
| Hand Eczema and Vitiligo |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In February, the company entered into an agreement with Sato Pharmaceutical to develop topical roflumilast in Japan. |
| 2024 | New Products/Services | In January, the company introduced ZORYVE (roflumilast) topical foam, 0.3%, in the US for treating seborrheic dermatitis. |
| 2023 | Regulatory Approval | In October, the company's Zoryve (roflumilast) cream 0.3% was approved by the US Food and Drug Administration for the topical treatment of plaque psoriasis in children ages 6 to 11 years. |
Competitor Comparison
| Key Parameters | Arcutis Biotherapeutics Inc | AbbVie Inc | Biofrontera Inc | Provectus Biopharmaceuticals Inc | Blacksmith Brands Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Westlake Village | North Chicago | Woburn | Knoxville | Tarrytown |
| State/Province | California | Illinois | Massachusetts | Tennessee | New York |
| No. of Employees | 296 | 50,000 | 85 | 4 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Patrick Heron | Chairman | Executive Board | 2019 | 51 |
| Frank Watanabe | President; Director; Chief Executive Officer | Executive Board | 2017 | 55 |
| David Topper | Chief Financial Officer | Senior Management | 2024 | - |
| Courtney Barton | Chief Compliance Officer; Vice President | Senior Management | - | - |
| Patrick E. Burnett | Senior Vice President; Chief Medical Officer | Senior Management | 2020 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward